Proposed Rule by CMS Offers Employers an Option for Supplemental Fertility Benefits, But Questions Remain About Scope and Impact

The Centers for Medicare & Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services (HHS), has published a proposed rule that introduces a new legal avenue for employers to provide supplemental fertility care benefits to their employees. This initiative, announced by the current administration, is being framed as an expansion of fertility coverage. However, a closer examination of the proposed regulation reveals that it offers employers the option to provide such benefits, rather than mandating them. Furthermore, the rule does not extend access to crucial fertility treatments like In Vitro Fertilization (IVF) within public health insurance programs such as Medicaid.

The nuances of this proposed rule have sparked considerable discussion regarding its actual impact on individuals seeking fertility assistance. While the intention is to provide employers with more flexibility in offering benefits, critics point out that this optional approach could lead to uneven access and potentially favor certain fertility treatments over others, particularly those that may not be as comprehensive or effective as IVF. The administration’s framing of the rule as an "expansion" is therefore subject to scrutiny, with many questioning whether it represents a genuine advancement in fertility care accessibility or a more limited, employer-driven approach.

Background and Context of the Proposed Rule

The emergence of this proposed rule is situated within a broader national conversation about reproductive healthcare access and the growing demand for fertility treatments. In recent years, advancements in assisted reproductive technologies (ART) have made it possible for millions of individuals and couples to overcome infertility and build their families. IVF, in particular, has become a cornerstone of fertility treatment, enabling a significant number of births annually. Despite its widespread use and success, the cost of IVF and other ART procedures remains a substantial barrier for many, often exceeding what insurance plans typically cover.

Historically, fertility benefits have been a patchwork of offerings, with coverage varying widely depending on employer, state laws, and insurance provider. Some states have enacted mandates requiring certain insurance plans to cover fertility treatments, including IVF, but these laws often have limitations, such as caps on the number of cycles or specific age restrictions. This lack of uniform coverage has created a system where access to fertility care is often determined by employment status or geographic location, leading to significant inequities.

The proposed rule from CMS aims to address this disparity by creating a federal pathway for employers to voluntarily offer supplemental fertility benefits. This initiative comes at a time when fertility challenges are increasingly recognized as a significant public health concern. According to the Centers for Disease Control and Prevention (CDC), approximately 12% of women aged 15-44 in the United States have a diagnosed fertility problem. For many, infertility can be a deeply distressing experience, impacting mental health, relationships, and overall well-being. The financial burden associated with fertility treatments, which can run into tens of thousands of dollars per cycle, further exacerbates these challenges.

Timeline and Key Provisions of the Proposed Rule

The proposed rule was published in the Federal Register on May 13, 2026, with the document identifier 2026-09479. This publication marked the official commencement of a public comment period, during which stakeholders, including healthcare providers, patient advocacy groups, employers, and the general public, can submit feedback and express their views on the proposed regulations. The timeline for the finalization of the rule will depend on the volume and nature of the comments received, as well as the administrative processes within HHS. Typically, after the comment period closes, agencies review the feedback, make necessary revisions to the proposed rule, and then issue a final rule.

The core of the proposed rule lies in its provision for "excepted fertility benefits." This classification allows employers to offer these benefits as a separate, supplemental package that is not subject to certain requirements of other employee benefit laws, such as the Mental Health Parity and Addiction Equity Act (MHPAEA) in its entirety, though proponents argue it could enhance parity in practice by facilitating coverage. The intention behind this "excepted" status is to provide employers with greater flexibility and potentially lower administrative burdens when designing and implementing fertility benefit plans.

Crucially, the proposed rule does not mandate the inclusion of specific fertility treatments. This means that employers who choose to offer these supplemental benefits could, in theory, opt to cover only a limited range of services. This is a point of significant concern for reproductive rights advocates and individuals seeking comprehensive fertility care. The rule, as proposed, allows for the possibility of employers covering what critics have termed "restricted IVF" or adopting other approaches to fertility health care that may not align with the most effective or widely accepted treatment protocols.

Concerns Regarding "Restricted IVF" and Employer Discretion

A central concern raised by organizations like Reproductive Rights is the potential for employers to implement fertility benefit plans that are not truly comprehensive. The proposed rule’s allowance for "excepted fertility benefits" could enable employers to offer coverage that focuses on less effective treatments or incorporates restrictive definitions of infertility. This could include emphasizing "lifestyle factors" as the primary cause of infertility, thereby potentially placing undue blame on individuals attempting to conceive, or discouraging the use of IVF, which is often the most successful ART method.

The administration’s rhetoric surrounding the rule has also drawn criticism. For example, President Trump’s statement at the time of the announcement, that the rule would "hopefully reduce the number of couples who ultimately need to resort to IVF," has been interpreted by many as a signal that the administration’s ultimate goal may not be to expand access to IVF, but rather to steer individuals away from it. This perspective is particularly concerning given that IVF is a critical tool for many individuals and couples facing infertility. The success rates of IVF have improved significantly over the years, offering a viable path to parenthood for those who might otherwise be unable to conceive.

The distinction between offering an option and establishing a requirement is critical. While the proposed rule provides a framework for employers to act, it does not compel them to do so. This means that employees of companies that do not choose to offer these supplemental benefits will continue to face the same challenges in accessing and affording fertility care. Furthermore, the nature of the benefits offered will be entirely at the employer’s discretion, leading to a potential for significant disparities in coverage even among employees of companies that do participate.

Supporting Data and the Need for Comprehensive Coverage

The demand for fertility treatments is substantial and growing. Data from the CDC’s National Assisted Reproductive Technology Surveillance System (NARTSS) consistently shows the significant number of ART cycles performed annually in the United States. In 2022, for instance, there were over 400,000 ART cycles performed, resulting in the birth of over 100,000 infants. These numbers underscore the importance of fertility treatments as a pathway to parenthood for a considerable portion of the population.

The financial burden of these treatments is equally significant. A single cycle of IVF can cost anywhere from $12,000 to $20,000 or more, not including the cost of medications, which can add several thousand dollars more. For individuals undergoing multiple cycles, the total cost can easily exceed $50,000 or $100,000. Employer-sponsored insurance coverage for fertility treatments is highly variable. A report by the National Conference of State Legislatures (NCSL) indicates that as of 2023, only 18 states had laws mandating some form of fertility coverage for private insurance plans, and these mandates often come with significant limitations.

The lack of comprehensive coverage disproportionately affects certain demographic groups. Lower-income individuals and those employed by smaller companies are less likely to have access to robust fertility benefits. This creates a system where the ability to pursue fertility treatment is often tied to socioeconomic status, further exacerbating existing health inequities.

Potential Implications and Broader Impact

The proposed rule from CMS, while offering a new avenue for employers, raises several critical questions about its long-term impact:

• Equity of Access: Will the optional nature of the rule lead to a wider gap in fertility care access, with some employees receiving comprehensive benefits while others receive none? The success of the rule in promoting equitable access will largely depend on the extent to which employers voluntarily adopt robust and inclusive fertility benefit plans.
• Scope of Covered Treatments: The potential for employers to offer "restricted IVF" or to de-emphasize effective treatments like IVF is a significant concern. This could lead to individuals pursuing less effective or more burdensome treatment paths, potentially impacting their chances of conception and increasing their overall financial and emotional strain.
• Impact on Public Programs: The proposed rule does not address the coverage of fertility treatments within public health insurance programs like Medicaid. This leaves a significant portion of the population without access to affordable fertility care, particularly those with lower incomes who rely on these programs.
• Administrative Complexity: While the "excepted benefits" classification aims to simplify administration, the practical implementation of these plans by employers, especially in ensuring genuine parity and avoiding discriminatory practices, could still present challenges.

Reactions from Stakeholders (Inferred)

While official statements from all parties directly reacting to this specific proposed rule may not yet be widely available, based on their established positions, certain reactions can be logically inferred:

• Reproductive Rights Advocates: Organizations focused on reproductive rights are likely to express concerns about the optional nature of the rule and the potential for employers to offer limited or restrictive fertility benefits. They will likely advocate for mandates that ensure comprehensive coverage of all medically necessary fertility treatments, including IVF, and for the expansion of coverage within public health insurance programs.
• Employer Organizations: Business groups and employer associations may view the proposed rule as a positive step, offering them greater flexibility in designing employee benefit packages. They might emphasize the administrative ease of offering supplemental benefits without stringent mandates. However, they may also express concerns about potential cost implications if the rule is interpreted in a way that necessitates significant employer contributions.
• Fertility Patient Advocacy Groups: Groups representing individuals and couples struggling with infertility are likely to welcome any initiative that could potentially increase access to fertility care. However, they will also be keenly interested in the specifics of the coverage offered, emphasizing the need for comprehensive benefits that include advanced treatments like IVF and address the significant financial burdens associated with fertility treatment.
• Healthcare Providers: Fertility clinics and medical professionals specializing in reproductive medicine will likely support measures that expand access to their services. They will be concerned with ensuring that any offered benefits are aligned with current medical standards and best practices for fertility treatment.

Analysis of Implications

The proposed rule by CMS represents a complex development in the landscape of fertility benefits. On one hand, it acknowledges the growing need for fertility care and provides a framework for employers to step in and offer support. This voluntary approach, proponents argue, could lead to a more diverse and adaptable set of fertility benefit options tailored to the specific needs of different workforces.

However, the rule’s optional nature and the potential for employers to offer restricted coverage are significant drawbacks. Without mandates, the promise of expanded access may not translate into tangible benefits for a large segment of the population. The emphasis on "excepted benefits" could inadvertently create a tiered system of care, where only those employed by forward-thinking or highly regulated companies receive truly comprehensive support.

Furthermore, the administration’s stated goal of reducing reliance on IVF, as articulated by President Trump, runs counter to the scientific consensus on effective fertility treatments. IVF remains the most successful ART method for many individuals and couples, and its de-emphasis could be detrimental to their family-building goals.

The proposed rule also highlights the ongoing debate about the role of government in regulating reproductive healthcare. While the rule seeks to facilitate employer-sponsored benefits, it sidesteps the more direct approach of mandating coverage or expanding access through public programs. This suggests a preference for market-based solutions, with the hope that competition and employee demand will drive employers to offer more comprehensive benefits.

Ultimately, the true impact of this proposed rule will depend on how it is implemented and received. The public comment period will be crucial in shaping the final regulation, and the willingness of employers to embrace robust and inclusive fertility benefit plans will determine whether this initiative truly expands access to much-needed fertility care or merely offers a limited, optional pathway with significant potential for inequity. The broader implications extend to the ongoing national dialogue about reproductive rights, healthcare access, and the fundamental right to build a family.

Learn more about ongoing attacks on IVF here.